NIB and Citadele lend 37 million Eur for the first Baltic alyse gene therapy center in Vilnius

The part financed by NIB is 22.5 million. EUR, and Citadele bank 14.5 million. Eur, banks announce.

The new gene therapy center will be the first and so far the only facility of its kind in the Baltic States. It will be equipped with research and production infrastructure that will help develop genetic disease treatment methods.

The center, which will be located in a building of approximately 8,000 square meters, plans to create more than 100 new jobs.

We appreciate the trust and financial loan provided by NIB and Citadele Bank for the development of the first gene therapy center in the Baltic States, which is one of the key parts of the Bio City project of the Northway Group. the completion of this center this year is a major step in our plans to create Europe’s largest biotechnology city in Vilnius, comments prof. Vladas Algirdas Bumelis, CEO of Celltechna.

currently, the life science industry generates about 2.5% of Lithuania’s GDP. The long-term strategy approved by the government extends to 2030. i dal increase to 5%

The borrower UAB Celltechna provides pharmaceutical and manufacturing services to pharmaceutical companies in Europe and the USA. The guarantor UAB Biotechpharma is a related company that provides services to pharmaceutical research companies developing new drugs.

By providing financing, we support the strategic development of Lithuania’s priority sector, Jeanette Vitasp, NIB’s vice-president and head of the loan department, is quoted in the announcement. According to her, the project will not only increase the competitiveness of oil in the rapidly developing area, but also provide great growth potential for the entire region.

We appreciate the opportunity to contribute to strengthening the leadership of the Lithuanian biotechnology and life sciences sector. Such strategic projects help create future-proof economies and promote consistent oil development, says Vaidas agnis, member of the board of Citadele Bank and head of the Business Banking Service for the Baltic States.

It is said that the new center will expand our products from biopharmaceuticals to gene therapy and will provide a solid foundation for the implementation of our ambitious long-term vision. In the next few years, more biotechnology-related factories and scientific research centers are planned to be built on the plot on Molt Road, thus consolidating life sciences in one place.

[{“title”:”V. A. Bumelis apie statom Bio City: investicijos siekt 7 mlrd. Eur, sukurtume 2.100 darbo viet”,”url”:”https://vz.lt/pramone/2023/11/16/v-a-bumelis-apie-statoma-bio-city-investicijos-siektu-7-mlrd-eur-sukurtume-2100-darbo-vietu”,”category”:”PREMIUM”,”profiles”:[1019,1020,1067,1633,1660,1670,1688,1873,2004]},{“title”:”VA Bumelio Bio City u aus timptelt vis Europe, but so far the money has gone to the USA”,”url”:”https://vz.lt/pramone/2023/11/23/va-bumelio -bio-city-uz-ausu-timpteltu-wisa-europa-but-money-so-far-who-walks-in-jav”,”category”:”PREMIUM”,”profiles”:[1020,1067,1633,1660,1670,1686,1873]}. -Lithuania-will-establish-as-one-of-the-main-biotechnology-centre”,”category”:”PREMIUM”,”profiles”:[1019,1020,1067,1633,1660,1670,1688,1872,1873,2097]}]